Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.22 BRL | -1.87% | -1.31% | +14.55% |
Jun. 14 | Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto | DJ |
Jun. 14 | Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 37.65 and 24.2 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.55% | 160B | - | ||
+50.70% | 791B | C+ | ||
+41.96% | 630B | B | ||
-7.15% | 350B | C+ | ||
+18.77% | 328B | B- | ||
+8.79% | 298B | C+ | ||
+18.02% | 246B | B+ | ||
+1.27% | 225B | A+ | ||
+11.95% | 218B | B- | ||
-4.38% | 156B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AMGN Stock
- AMGN34 Stock
- Ratings Amgen Inc.